Patents and Innovation in Cancer Therapeutics: Lessons from CellPro

Avital Bar-Shalom, Robert Cook-Deegan

    Research output: Contribution to journalArticle

    32 Scopus citations

    Abstract

    This article discusses the interaction between intellectual property and cancer treatment. CellPro developed a stem cell separation technology based on research at the Fred Hutchinson Cancer Center. A patent with broad claims to bone marrow stem cell antibodies had been awarded to Johns Hopkins University and licensed to Baxter Healthcare under the 1980 Bayh-Dole Act to promote commercial use of inventions from federally funded research. CellPro got FDA approval more than two years before Baxter but lost patent infringement litigation. NIH elected not to compel Hopkins to license its patents to CellPro. CellPro went out of business, selling its technology to its competitor. Decisions at both firms and university licensing offices, and policies at the Patent and Trademark Office, NIH, and the courts influenced the outcome.

    Original languageEnglish (US)
    Pages (from-to)637-676
    Number of pages40
    JournalMilbank Quarterly
    Volume80
    Issue number4
    DOIs
    StatePublished - 2002

    ASJC Scopus subject areas

    • Health Policy
    • Public Health, Environmental and Occupational Health

    Fingerprint Dive into the research topics of 'Patents and Innovation in Cancer Therapeutics: Lessons from CellPro'. Together they form a unique fingerprint.

  • Cite this